Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

House Panel Maps Out Plan For Cures Oversight, Obamacare Repeal

Executive Summary

The House Energy and Commerce has released its two-year oversight plans in advance of an organizational meeting. The plan features close attention to federal implementation of the 21st Century Cures Act, the efficiency of FDA product reviews, and work to repeal and replace the Affordable Care Act.

You may also be interested in...



Industry 'Encouraged' By Trump Exec Order To Undo ACA, Device Tax

Industry cheered one of President Trump's first executive orders filed Jan. 20, calling on HHS and others in the executive branch to "waive, defer, grant exemptions" from Affordable Care Act provisions for industry imposing burdens on them, including the costs of taxes and fees on "makers of medical devices."

21st Century Cures: Device Provisions

Dozens of reforms impacting the medtech sector were signed into law Dec. 13 as part of the 21st Century Cures Act. Here's a breakdown of the provisions most important to device- and diagnostic-makers.

Senate Adopts Cures Bill By Big Margin; FDA Could Tap $20m More In 2017

The Senate approved the same 21st Century Cures bill passed by the House last week on a 94-5 tally; the bill is expected to be quickly signed by President Obama. Provisions for extra dollars for FDA in the bill means that even with a plan by Congress to adopt a continuing resolution this week freezing FDA funding until April 28, the agency can rely on an additional $20 million set aside for it in Cures in the new year.

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT104350

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel